Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q2 2022 Earnings Presentation
18 slides from Sanara Medtech's earnings presentation, Aug 15, 2022
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview (Nasdaq: SMTI) August 2022 Evidence Based Healing
Slide 2: Disclaimers
Disclaimers v This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements ot
Slide 3: Company Overview
Company Overview . Sanara “ MedTech Evidence Based Healing
Slide 4: About Sanara MedTech
About Sanara MedTech With a focus on improving patient outcomes through evidence-based healing technologies, Sanara MedTech Inc. provides products and technologies for surgical and chronic wound care Highly competitive propriety product portfolio — CellerateRX Surgical Activated Collagen — BIAKOS An
Slide 5: Sanara's Six Wound Care and Surgical Site Therapy Focus Areas
Sanara’s Six Wound Care and Surgical Site Therapy Focus Areas Sanara’s strategy is to create a value proposition through the use of efficacious products and services in the appropriate care settings for wound and skin care Biofilm Removal Hydrolyzed Collagen o Debrider technology licensed and curren
Slide 6: Surgical and Chronic Wound Disruptive Strategies
Surgical and Chronic Wound Disruptive Strategies «- Sanara * MedTech Evidence Based Healing
Slide 7: Surgical Wound Disruptive Strategies
Surgical Wound Disruptive Strategies Sanara MedTech urgical Wound Market a. ee Future Market Growth o Surgical Wounds are the largest Medicare spend area in wound care totaling $11.7B (including cost of infections)” co 15.3M surgeries in the U.S. each year (excluding ocular surgery), 7.8M in ASCs an
Slide 8: Chronic Wound Care Disruption
Chronic Wound Care Disruption What is the Wound Care Industry Missing Today? Early, accurate diagnosis and intervention Comorbidity recognition and management Education / standard of care for primary providers Access to specialty wound care Product and service innovation Value-based reimbursement mo
Slide 9: SMTI Surgical Division
SMTI Surgical Division #2 Sanara ° MedTech Evidence Based Healing
Slide 10: Surgical Products
Surgical Products Surgical Overview + 35 field sales managers CellerateRX Surgical sold in 590 hospitals/ASCs in the TTM s CellerateRX Surgical sold in hospitals/ASCs across 27 states) in the TTM CellerateRX Surgical approved to be sold in 1,580 hospitals/ASCs Total estimated available market in the
Slide 11: SMTI Wound and Virtual Consult Strategy
SMTI Wound and Virtual Consult Strategy
Slide 12: A Comprehensive Solution for Wound Care
Sanara MedTech A Comprehensive Solution for Wound Care Sanara MedTech The components of Sanara’s offering are complementary and promote improved outcomes. Proprietary Diagnostics Virtual Consults (Wound and Dermatology) Proprietary Products WounDerm EMR + Designed to quantify key biomarkers that dic
Slide 13: Sanara MedTech Portfolio
Sanara MedTech Portfolio Innovative, Comprehensive, Complementary Diagnostics/Treatment Algorithms EMR and Mobile App Under development + Under development + | MGroup Strategies + Wound Care virtual consult services + Novel and disruptive approach to unmet need in * Licensed in 50 states Provider to
Slide 14: Research and Development
Research and Development #2 Sanara ° MedTech Evidence Based Healing
Slide 15: Rochal Technologies (R&D Division)
Rochal Technologies (R&D Division) Research Team Product Experience Core Capabilities Leader in commercializing technology innovations in wounds, skin care, and burns Ability to manage product development from concept to commercialization 12 employees including 9 scientists/engineers Based in San An
Slide 16: Financial Overview
Financial Overview . Sanara “ MedTech Evidence Based Healing
Slide 17: Q2 2022 Financial Highlights
Q2 2022 Financial Highlights Overview + Revenue + For the three months ended June 30, 2022, we generated net revenues of $9.7 million compared to net revenues of $6.3 million for the three months ended June 30, 2021, representing a 54% increase from the prior year period. + For the six months ended
Slide 18: Questions
18 Questions . Sanara “ MedTech Evidence Based Healing